Hsu Chih-Wei, Lee Yu, Lee Chun-Yi, Lin Pao-Yen
Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
Clin Neuropharmacol. 2017 May/Jun;40(3):147-148. doi: 10.1097/WNF.0000000000000215.
Pisa syndrome (PS) is a state of dystonic muscle contraction with a marked truncal deviation to one side. It is an uncommon adverse effect of antipsychotic drugs, but is rarely reported in patients receiving acetylcholinesterase inhibitors, especially rivastigmine. We present a 57-year-old female patient with Alzheimer disease who began to develop symptoms of dementia at the age of 51 years. She was observed to have symptoms of PS after continuous use of rivastigmine (9 mg/d) for nearly 2 years. The PS symptoms improved after the dose of rivastigmine was reduced but recurred when the dose was added back to 9 mg/d. Finally, after we decreased the dose to 4.5 mg/d, her PS symptoms were remitted. This report reminds us that clinicians need to be cautious about the risk of PS when prescribing rivastigmine in a patient with early-onset Alzheimer disease.
Pisa综合征(PS)是一种肌张力障碍性肌肉收缩状态,伴有明显的躯干向一侧偏斜。它是抗精神病药物的一种罕见不良反应,但在接受乙酰胆碱酯酶抑制剂(尤其是 rivastigmine)治疗的患者中很少有报道。我们报告一名57岁的阿尔茨海默病女性患者,她在51岁时开始出现痴呆症状。在连续使用 rivastigmine(9毫克/天)近2年后,观察到她出现了PS症状。当rivastigmine剂量减少后,PS症状有所改善,但当剂量恢复到9毫克/天时又复发。最后,当我们将剂量降至4.5毫克/天时,她的PS症状得到缓解。本报告提醒我们,临床医生在为早发性阿尔茨海默病患者开rivastigmine处方时,需要谨慎考虑PS的风险。